Subacute toxicity study of lacidipine nanoformulation

Rupesh Shirodkar, Neetinkumar Reddy, Nitesh Kumar, Grandhi Ramalingayya, Srinivas Mutalik, Shaila Lewis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of the present work was to perform subacute toxicity study of lacidipine nanoformulation in Wistar rats. Solid lipid nanoparticles (SLNs) of lacidipine was formulated using ultrasound dispersion technique. Subacute toxicity study was carried out by administrating orally SLNs containing 0.140, 0.350, and 0.875 mg of lacidipine as low, medium and high dose per kg body weight, respectively, along with blank formulation and standard drug (lacidipine). Control group rats received Milli Q water. Doses were administered once daily over a period of 28 days. Animals were observed for morphological parameters of toxicity during study period and their body weight were recorded once weekly. Overnight fasted rats were sacrificed on 29th day and assessment of haematological, biochemical parameters and histopathological analysis of brain, heart, kidney and liver were carried out. The results suggest SLNs formulation of lacidipine do not cause toxicity or adverse effect in rats.

Original languageEnglish
Pages (from-to)1526-1533
Number of pages8
JournalLatin American Journal of Pharmacy
Volume34
Issue number8
Publication statusPublished - 26-09-2015

Fingerprint

Nanoparticles
Lipids
Body Weight
Drug Compounding
Wistar Rats
lacidipine
Kidney
Control Groups
Water
Liver
Brain

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

Shirodkar, Rupesh ; Reddy, Neetinkumar ; Kumar, Nitesh ; Ramalingayya, Grandhi ; Mutalik, Srinivas ; Lewis, Shaila. / Subacute toxicity study of lacidipine nanoformulation. In: Latin American Journal of Pharmacy. 2015 ; Vol. 34, No. 8. pp. 1526-1533.
@article{e5b1c9d336fe414bae0cfa3bdb5c2e5d,
title = "Subacute toxicity study of lacidipine nanoformulation",
abstract = "The aim of the present work was to perform subacute toxicity study of lacidipine nanoformulation in Wistar rats. Solid lipid nanoparticles (SLNs) of lacidipine was formulated using ultrasound dispersion technique. Subacute toxicity study was carried out by administrating orally SLNs containing 0.140, 0.350, and 0.875 mg of lacidipine as low, medium and high dose per kg body weight, respectively, along with blank formulation and standard drug (lacidipine). Control group rats received Milli Q water. Doses were administered once daily over a period of 28 days. Animals were observed for morphological parameters of toxicity during study period and their body weight were recorded once weekly. Overnight fasted rats were sacrificed on 29th day and assessment of haematological, biochemical parameters and histopathological analysis of brain, heart, kidney and liver were carried out. The results suggest SLNs formulation of lacidipine do not cause toxicity or adverse effect in rats.",
author = "Rupesh Shirodkar and Neetinkumar Reddy and Nitesh Kumar and Grandhi Ramalingayya and Srinivas Mutalik and Shaila Lewis",
year = "2015",
month = "9",
day = "26",
language = "English",
volume = "34",
pages = "1526--1533",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "8",

}

Shirodkar, R, Reddy, N, Kumar, N, Ramalingayya, G, Mutalik, S & Lewis, S 2015, 'Subacute toxicity study of lacidipine nanoformulation', Latin American Journal of Pharmacy, vol. 34, no. 8, pp. 1526-1533.

Subacute toxicity study of lacidipine nanoformulation. / Shirodkar, Rupesh; Reddy, Neetinkumar; Kumar, Nitesh; Ramalingayya, Grandhi; Mutalik, Srinivas; Lewis, Shaila.

In: Latin American Journal of Pharmacy, Vol. 34, No. 8, 26.09.2015, p. 1526-1533.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subacute toxicity study of lacidipine nanoformulation

AU - Shirodkar, Rupesh

AU - Reddy, Neetinkumar

AU - Kumar, Nitesh

AU - Ramalingayya, Grandhi

AU - Mutalik, Srinivas

AU - Lewis, Shaila

PY - 2015/9/26

Y1 - 2015/9/26

N2 - The aim of the present work was to perform subacute toxicity study of lacidipine nanoformulation in Wistar rats. Solid lipid nanoparticles (SLNs) of lacidipine was formulated using ultrasound dispersion technique. Subacute toxicity study was carried out by administrating orally SLNs containing 0.140, 0.350, and 0.875 mg of lacidipine as low, medium and high dose per kg body weight, respectively, along with blank formulation and standard drug (lacidipine). Control group rats received Milli Q water. Doses were administered once daily over a period of 28 days. Animals were observed for morphological parameters of toxicity during study period and their body weight were recorded once weekly. Overnight fasted rats were sacrificed on 29th day and assessment of haematological, biochemical parameters and histopathological analysis of brain, heart, kidney and liver were carried out. The results suggest SLNs formulation of lacidipine do not cause toxicity or adverse effect in rats.

AB - The aim of the present work was to perform subacute toxicity study of lacidipine nanoformulation in Wistar rats. Solid lipid nanoparticles (SLNs) of lacidipine was formulated using ultrasound dispersion technique. Subacute toxicity study was carried out by administrating orally SLNs containing 0.140, 0.350, and 0.875 mg of lacidipine as low, medium and high dose per kg body weight, respectively, along with blank formulation and standard drug (lacidipine). Control group rats received Milli Q water. Doses were administered once daily over a period of 28 days. Animals were observed for morphological parameters of toxicity during study period and their body weight were recorded once weekly. Overnight fasted rats were sacrificed on 29th day and assessment of haematological, biochemical parameters and histopathological analysis of brain, heart, kidney and liver were carried out. The results suggest SLNs formulation of lacidipine do not cause toxicity or adverse effect in rats.

UR - http://www.scopus.com/inward/record.url?scp=84942258129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942258129&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 1526

EP - 1533

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 8

ER -